Fluoroquinolones are among the drugs of choice for treatment of salmonella infections. However, 20 fluroquinolone resistance is increasing in salmonella due to chromosomal mutations in the quinolone 21 resistance-determining region (QRDR) of the topoisomerase genes gyrA, gyrB, parC and parE and/or plasmid-22 mediated quinolone resistance (PMQR) mechanisms including qnr variants, aac(6')- qepA and oqxAB. 23 Some of these cause only subtle increases of the MIC i.e, MICs ranging from 0.12 -0.25 mg/L for ciprofloxacin 24 (just above the wild type MIC of ≤0.06 mg/L). These isolates are difficult to detect with standard ciprofloxacin 25 disk diffusion, and plasmid mediated resistance such as qnr are often not detected by the nalidixic acid screen 26 test. We evaluated 16 quinolone/fluoroquinolone disks for their ability to detect low-level resistant Salmonella 27 non-typhi isolates. A total of 153 Salmonella isolates characterized for the presence (N=104) or absence (N=49) 28 of gyrA/parC topoisomerase mutations, qnrA, qnrB, qnrD, qnrS, aac(6')-lb-cr or qepA genes were investigated. 29
Introduction 37
Human infections caused by Salmonella enterica subspecies enterica represent a major burden worldwide (1) . 38
Typhoidal Salmonella (Salmonella Typhi and Paratyphi A) cause enteric fever, a severe systemic and febrile 39 illness, whereas non-typhoidal serotypes primarily cause self-limiting diarrhoea with occasional bacteraemia. 40
Timely treatment with antimicrobial agents is critical for optimal treatment of both enteric fever and invasive 41 non-typhoidal Salmonella infections. Fluoroquinolones (e.g. ciprofloxacin) are highly efficient against fully 42 susceptible (i.e. isolates without any resistance mechanisms) whereas their efficacy is in doubt as soon as any 43 resistance can be detected and there is concern about the rapidly increasing fluoroquinolone resistance in 44
Salmonella (2-5). 45
Fluoroquinolone resistance in Salmonella is mainly caused by chromosomal mutations in the 46 quinolone resistance-determining region (QRDR) of the topoisomerase genes gyrA, gyrB, parC and parE (6,7). 47
Valencia, CA, USA) according to the manufacturer's instructions, and subsequently sequenced on an ABI PRISM 99 373 DNA Sequencer (PE Applied Biosystems, Foster City, CA, USA). 100 101
Antimicrobial Susceptibility Testing 102
MICs for ciprofloxacin, levofloxacin, nalidixic acid and ofloxacin were determined using broth microdilution 103 (BMD) according to the ISO standard 20776-1. Testing was performed using customized frozen (TREK 104 Diagnostics/Thermo Fisher Scientific, Oakwood, OH) or lyophilized (TREK Diagnostics/Thermo Fisher Scientific, 105
Basingstoke, United Kingdom) panels. 106
Disk diffusion (DD) was performed according to EUCAST i.e. a total of 87 isolates x 2 media x 2 persons = 348 readings per disk. Four disks were included in a second 119 round of testing (ciprofloxacin 1 µg, enoxacin 10 µg, norfloxacin 2 µg and pefloxacin 5 µg) along with 120 ciprofloxacin (5 µg), nalidixic acid (30 µg), levofloxacin (5 µg), and ofloxacin (5 µg) disks. This second evaluation 121 on October 16, 2017 by guest http://jcm.asm.org/ Downloaded from was performed at three laboratories (EDL, SSI and NARMS-CDC) and included 126 isolates (Table 2) Once we had chosen to develop the method on the pefloxacin disk, two steps were taken to validate the disk 134 diffusion assay. As a first step, differences in pefloxacin disk potency among disks from different manufacturers 135 was assessed by testing 24 selected isolates against pefloxacin 5 µg disks from Becton Dickinson, Bio-Rad 136 (Marnes-la-Coquette, France), MAST Diagnostic (Bootle,Merseyside, UK) and Oxoid. The disk potency was 137 investigated independently at two sites using a bioassay (27) . The results for each of the 16 disks are shown in Table 1 . Since there was a perfect correlation between MICs 158 and resistance mechanisms for all three fluoroquinolones, disk diffusion results were correlated to 159
ciprofloxacin MIC values and resistance mechanisms throughout. Our results confirmed that the nalidixic acid 160 30 µg disk is reliable only for the detection of isolates with topoisomerase mutations. A considerable overlap, 161 and thus poor distinction, between wild type and non-wild type isolates was also observed for the ciprofloxacin 162 2 µg and pefloxacin 5 µg disks were able to distinguish between wild type and non-wild type isolates and were 164 for this reason considered for the next stage of the study where three laboratories (EDL, SSI and CDC) were 165 involved in the evaluation (Table 2) . 166
Again, excellent results were obtained with the pefloxacin 5 µg disk -only two of 756 readings 167 (0.3%) resulted in overlapping zone diameters between isolates with and without a resistance mechanism. Our studies confirmed that none of the traditional fluoroquinolone disks nor the nalidixic acid 233 disk were able to discriminate between isolates without (wild type) and with (non-wild type) resistance 234 mechanisms. We also confirmed that MIC determination by broth microdilution with either ciprofloxacin, 235 levofloxacin or ofloxacin, was able to reliably discriminate between wild-type and non-wild type isolates. 236
We chose to develop pefloxacin because of its consistently good performance on several brands 237 of MH media in distinguishing wild type and non-wild type isolates, because pefloxacin behaved slightly better 238 than the other disks when looking at individual brands of MH agar, because we had to choose one disk for 239 further development and pefloxacin disks were available from four manufacturers. 240
However, we also identified drawbacks with the choice of pefloxacin. It does not detect 241 resistance mediated by the aac(6')-Ib-cr gene as ciprofloxacin and norfloxacin are the only fluoroquinolones 242 which possess the piperazynil amide side chain which is the target for the enzyme encoded by aac(6′) . 243
This resistance type seems to be very rare and the one isolate we were able to include had a second 244 unrecognized resistance mechanism as it was resistant to levofloxacin and ofloxacin. Furthermore, despite the 245 fact that we identified at least four manufacturers, pefloxacin disks are currently not commercially available in 246 some countries including the US. 
